Suggestion of novel hormone therapy for metastatic prostate cancer / 中华泌尿外科杂志

ABSTRACT

Several phase Ⅲ clinical trials have confirmed that androgen deprivation therapy combined with novel hormone therapy can prolong the survival of patients with metastatic prostate cancer. It has become a commonly used scheme in clinical practice. The physical condition, concomitant diseases and economic status of patients, side effects, accessibility, costs and approved indications of drugs should also be considered when selecting the novel hormone therapy drugs for these patients. The sequential use of novel hormone therapy drugs and the conversion of corticosteroids benefit some patients, which can be selected carefully.